|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, further molecular testing with Archer fusion assay revealed a novel NCOA4-RET gene fusion, adding it to the list of multiple kinase fusions originally reported in these tumors.
|
30938880 |
2019 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Next-generation sequencing analysis detected a NCOA4-RET fusion transcript joining exon 7 or 8 of NCOA4 gene and exon 12 of RET gene in 6 cases of intercalated duct type IC; and a novel TRIM27-RET fusion transcript between exons 3 and 12 in 2 cases of salivary gland tumors displaying histologic and immunohistochemical features typical of apocrine IC.
|
30045065 |
2018 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
BRAF<sup>V600E</sup> was associated with older age and larger tumor size (p < 0.05), and RET/PTC3 was associated with a larger tumor size and multifocality (p < 0.05).
|
27849443 |
2017 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Thyroid nodule fine-needle aspiration biopsy samples and tumor tissue at the time of thyroidectomy were used to test for somatic genetic mutations (BRAF V600E, NRAS, KRAS, NTRK1, RET/PTC1, and RET/PTC3).
|
21190444 |
2011 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
During tumour development a large heterogeneity occurred in the Tg-RET/PTC3 model within a same tumour or within a same thyroid lobe.
|
18985036 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Gene expression in RET/PTC3 and E7 transgenic mouse thyroids: RET/PTC3 but not E7 tumors are partial and transient models of human papillary thyroid cancers.
|
18583418 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RT-PCR was also performed with two different primer sets for RET/PTC1, RET/PTC2, and RET/PTC3 followed by Southern hybridization in the first 62 tumors.
|
15876154 |
2005 |
|
Neoplasms
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We and others have shown that RET-PTC3 rearrangements are associated with the solid morphology seen in these short latency tumours, while classical papillary carcinomas more often show RET-PTC1 rearrangements.
|
15150580 |
2004 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We aimed to assess the prevalence of the common ret chimeric transcripts (ret/PTC-1 and ret/PTC-3) in a group of sporadic PTC and correlate them with tumor morphology.
|
12574236 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
RET/PTC1 tends to be more common in tumors with typical papillary growth and microcarcinomas and to have a more benign clinical course, whereas RET/PTC3 in some populations shows a strong correlation with the solid variant of papillary carcinoma and more aggressive tumor behavior.
|
12114746 |
2002 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Labeling was associated with the tumor cells while little if any ARA70 mRNA was observed in stromal cells associated with the carcinoma.
|
11161850 |
2001 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Remarkably, only 20% of HER2-positive tumors expressed both AR and ARA70, while 43% of HER2-negative tumors expressed both of these elements of the AR signaling pathway.
|
11561770 |
2001 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Surprisingly, the alignment of ELE1 and RET introns in opposite orientation revealed that in each tumor the position of the break in one gene corresponded to the position of the break in the other gene.
|
10597232 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Seven PTC1-positive tumors and one PTC3-positive tumor (8%), but none with the new variants or other variants of PTC1, 2 or 3 could be detected.
|
10367631 |
1999 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
We examined the expression of ret/PTC in 99 German papillary thyroid carcinomas, including two recently described new variants of ret/PTC3 and identified eight ret/PTC-positive tumours (8%) but none with the new variants.
|
9528832 |
1998 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Notably, in all sporadic tumors and in one post-Chernobyl tumor the ELE1/RET recombination corresponded with short sequences of homology (3-7 nt) between the two rearranging genes.
|
9192845 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
However, the types of ret/PTC vary between these two populations, with ret/PTC3 present more commonly in post-Chernobyl tumors.
|
9135009 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Our data concerning the radiation-associated tumors, showed that: (1) the overall frequency of ret rearrangements was 84% in papillary carcinomas (16/19) and 45% (9/20) in follicular adenomas; (2) in contrast with the results obtained in the Chernobyl tumors, the most frequently observed chimeric gene was RET/PTC1 instead of the RET/PTC3 and (3) all the tumors were negative for RET/PTC2.
|
9315093 |
1997 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
In this study, we have successfully amplified the chimeric introns resulting from these inversions, ranging from 1.4 to 10 kb, from four of five tumors known to contain the ret/PTC-1 oncogene (where c-ret rearranges with the H4 gene), and from 1/1 tumors containing the ret/PTC-3 oncogene (where c-ret rearranges with the ele1 gene).
|
8634704 |
1995 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
The karyotype of two RET/PTC3 positive tumors did not show any evidence of chromosome 10 abnormalities.
|
7529046 |
1994 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Finally we provide evidence indicating that the rearrangement leading to the generation of RET/PTC3 occurred in vivo in the original tumor DNA.
|
8290261 |
1994 |